Replies to post #251189 on Biotech Values

[vinmantoo]

There is data that shingrix (and before that zostavax) is associated with lower rates of dementia. GSK talks about this and that they may soon start a more rigorous study to flesh this out pending discussion with regulators. I haven’t seen the data and for all I know this is more correlation than causation

Thanks for that info dewophile. I am in my later 60s so already got Shingirx. While vaccine for any specific virus might lower risk in a subset of cases, the key is to understand and combat the physiological response or lack thereof which leads to dementia so it can be slowed in many if not most cases regardless of the causative agent. There are also indicatiosn that "brain exercise" may slow dementia.

https://www.webmd.com/alzheimers/preventing-dementia-brain-exercises

[iwfal]

There is data that shingrix (and before that zostavax) is associated with lower rates of dementia.

Similarly there is also data ppl getting treated for oral herpes… have lower rates of Alzheimer’s (altho, IIRC, it was one sex and not the other). And I think I’ve seen one other vaccine that had similar. So seems likely to be real?

[semi_infinite]

The GSK data set is pretty close to getting a randomized trial the way NHS in the UK implemented Shingrix vaccine eligibility. The difference in long term follow-up data is pretty stark.

[DewDiligence]

Good news/bad news for GSK’s Shingrix:

https://www.gsk.com/en-gb/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/#

Shingrix’s protection is longer lasting than most people expected. Corollary: It’s unlikely that patients will need booster shots (beyond the initial two-dose regimen).